Cargando…

Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker

BACKGROUND: Pembrolizumab and cetuximab are antibodies under investigation in head and neck squamous cell carcinoma (HNSCC) either as single agents or combined with cisplatin and other chemotherapeutic drugs, e.g., 5-fluorouracil and/or docetaxel. However, also the combination of both antibodies may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berszin, Michael, Michaelides, Ioannis, Siemert, Julia, Röhl, Louisa, Wellhausen, Jana, Wald, Theresa, Bohr, Christopher, Künzel, Julian, Gradistanac, Tanja, Dietz, Andreas, Zebralla, Veit, Pirlich, Markus, Wiegand, Susanne, Wichmann, Gunnar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918678/ https://www.ncbi.nlm.nih.gov/pubmed/35296001 http://dx.doi.org/10.3389/fonc.2022.795277

Ejemplares similares

Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome
por: Röhl, Louisa, et al.
Publicado: (2023)

High-Risk Human Papillomavirus (HR-HPV) DNA Detection in Mouthwashes for Diagnosis of HPV-Driven Oropharynx Cancer and Its Curative Therapy—A Feasibility Study
por: Loermann, Gera, et al.
Publicado: (2022)

Frailty Assessed with FRAIL Scale and G8 Questionnaire Predicts Severe Postoperative Complications in Patients Receiving Major Head and Neck Surgery
por: Kunz, Viktor, et al.
Publicado: (2022)

Standardized Diagnostics Including PET-CT Imaging, Bilateral Tonsillectomy and Neck Dissection Followed by Risk-Adapted Post-Operative Treatment Favoring Radio-Chemotherapy Improve Survival of Neck Squamous Cell Carcinoma of Unknown Primary Patients
por: Wichmann, Gunnar, et al.
Publicado: (2021)

Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Siemert, Julia, et al.
Publicado: (2021)

Standardized Diagnostic Workup and Patient-Centered Decision Making for Surgery and Neck Dissection Followed by Risk-Factor Adapted Adjuvant Therapy Improve Loco-Regional Control in Local Advanced Oral Squamous Cell Carcinoma
por: Wichmann, Gunnar, et al.
Publicado: (2021)

Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?
por: Lübbers, Katharina, et al.
Publicado: (2021)

Web-Based Patient-Reported Outcomes for ENT Patients—Evaluation of the Status Quo, Patients’ View, and Future Perspectives
por: Wald, Theresa, et al.
Publicado: (2022)

Dysphagia, voice problems, and pain in head and neck cancer patients
por: Zebralla, Veit, et al.
Publicado: (2021)

Course of Self-Reported Dysphagia, Voice Impairment and Pain in Head and Neck Cancer Survivors
por: Zebralla, Veit, et al.
Publicado: (2021)

Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population
por: Hammermüller, C., et al.
Publicado: (2021)

Obtaining Patient-Reported Outcomes Electronically With “OncoFunction” in Head and Neck Cancer Patients During Aftercare
por: Zebralla, Veit, et al.
Publicado: (2020)

Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients
por: Cedra, Susan, et al.
Publicado: (2017)

Monitoring and Evaluation of Late Functional Outcome in Post-treatment Follow-Up in Clinical Routine Setting
por: Zebralla, Veit, et al.
Publicado: (2019)

Keyword-augmented and semi-automatic generation of FESS reports: a proof-of-concept study
por: Kunz, V., et al.
Publicado: (2022)

Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment
por: Wiegand, Susanne, et al.
Publicado: (2019)

Malignant Vascular Tumors of the Head and Neck—Which Type of Therapy Works Best?
por: Wiegand, Susanne, et al.
Publicado: (2021)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Is High-Risk Sexual Behavior a Risk Factor for Oropharyngeal Cancer?
por: Wichmann, Gunnar, et al.
Publicado: (2023)

Laryngeal Preservation Approaches: Considerations for New Selection Criteria Based on the DeLOS-II Trial
por: Dietz, Andreas, et al.
Publicado: (2019)

Significance of Extranodal Extension in Surgically Treated HPV-Positive Oropharyngeal Carcinomas
por: Beltz, Anna, et al.
Publicado: (2020)

Adenoid cystic carcinoma of the salivary glands: a pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis
por: Michaelides, Ioannis, et al.
Publicado: (2023)

Efficacy of sirolimus in children with lymphatic malformations of the head and neck
por: Wiegand, S., et al.
Publicado: (2022)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
por: Leuteritz, Katja, et al.
Publicado: (2022)

Development of a Human Leukocyte Antigen Score to Predict Progression-Free Survival in Head and Neck Squamous Cell Carcinoma Patients
por: Wichmann, Gunnar, et al.
Publicado: (2018)

Discrimination of Head and Neck Squamous Cell Carcinoma Patients and Healthy Adults by 10-Color Flow Cytometry: Development of a Score Based on Leukocyte Subsets
por: Wichmann, Gunnar, et al.
Publicado: (2019)

A Radiomics-Based Machine Learning Perspective on the Parotid Gland as a Potential Surrogate Marker for HPV in Oropharyngeal Cancer
por: Prasse, Gordian, et al.
Publicado: (2023)

Routine restaging after primary non-surgical treatment of laryngeal squamous cell carcinoma—a review
por: Seebauer, Caroline Theresa, et al.
Publicado: (2020)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Association between malformation type, location and functional deficits in lymphatic malformations of the head and neck in children
por: Wiegand, Susanne, et al.
Publicado: (2023)

Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences
por: Dietz, Andreas, et al.
Publicado: (2011)

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
por: Küpper, Clemens, et al.
Publicado: (2019)

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial
por: Wiegand, Susanne, et al.
Publicado: (2023)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Predictive risk factors for lymph node metastasis in patients with resected non-small cell lung cancer: a case control study
por: Moulla, Yusef, et al.
Publicado: (2019)

Correction to: Predictive risk factors for lymph node metastasis in patients with resected non-small cell lung cancer: a case control study
por: Moulla, Yusef, et al.
Publicado: (2019)

Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies
por: Sucher, Elisabeth, et al.
Publicado: (2019)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_r01licci26ntiupk8t7amee6jb